A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers

An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of CSL112 in healthy volunteers after multiple infusions.

Inclusion Criteria:

• Healthy males and females aged 18 years to less than 55 years
• Body weight 50kg or greater
• Body mass index (BMI) between 18 and 42.0 kg/m2

Exclusion Criteria:

• Evidence of a clinically significant medical condition, disorder or disease
• Evidence of hepatobiliary disease
• Any clinically relevant abnormal laboratory test result
• Evidence or history of alcohol or substance abuse